 InflaRx NV NASDAQ: IFRX has announced new data Phase 2b SHINE study, evaluating vilobelimab IFX-1 in moderate and severe Hurley Stage II and III hidradenitis suppurativa HS, a chronic skin condition characterized by the formation of painful lumps under the skin typically in the armpit, groin and genitalia regions. Updated data demonstrated dose-dependent suppression of elevated C5a levels. 